Johnson & Johnson has partnered with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases, investing $785 million and securing an exclusive $2.58 billion acquisition option.
Written By: Umesh Hanumante,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson has entered into a strategic collaboration with Sail Biomedicines to develop in vivo chimeric antigen receptor T-cell (CAR-T) therapies for immune-mediated diseases, marking a significant expansion of its immunology and cell therapy portfolio. The agreement includes an exclusive option for Johnson & Johnson to acquire Sail for $2.58 billion, alongside an equity investment and development collaboration focused on advancing Sail’s lead program and platform technology.
The transaction combines Johnson & Johnson’s expertise in immunology and oncology cell therapies with Sail’s in vivo CAR-T platform, which aims to generate CAR-T cells directly within a patient’s body rather than manufacturing them outside the body before reinfusion.
In Vivo CAR-T Platform Targets Immune System Reset
Conventional CAR-T therapies require collecting a patient’s T cells, genetically engineering them in specialized manufacturing facilities, and reinfusing them after expansion. This process is complex, time-consuming, and costly.
Sail’s in vivo CAR-T platform instead delivers genetic instructions directly into the body, enabling immune cells to be reprogrammed in vivo. This approach could simplify manufacturing, improve treatment accessibility, and support scalable production while maintaining the potential for durable disease control.
The lead program is being developed for immune-mediated diseases, where long-lasting immune system reprogramming could offer sustained clinical benefit and potentially modify the underlying disease rather than providing temporary symptom control.
Immune-mediated disorders remain a major source of chronic disability worldwide, and many patients continue to experience incomplete disease control despite advances in biologics and targeted therapies.
Collaboration Supports Expansion Across Multiple Programs
Beyond the lead immunology candidate, the collaboration provides incentives to broaden Sail’s in vivo CAR-T platform across additional therapeutic targets over time.
Johnson & Johnson said the agreement complements its established leadership in immunology while extending its CAR-T expertise beyond oncology into immune-mediated diseases. The collaboration also expands the company’s capabilities in immune system reprogramming and creates opportunities to develop future therapies across multiple complex diseases.
Under the financial terms of the agreement, Johnson & Johnson will provide total initial payments of $785 million, including a $465 million equity investment in Sail. The deal also includes up to $140 million in contingent development milestone payments.
If Johnson & Johnson exercises its exclusive acquisition option, it will pay an additional $2.58 billion to acquire Sail.
Leadership Highlights Strategic Importance
John Reed, Executive Vice President of Innovative Medicine Research & Development at Johnson & Johnson, said patients with serious immune-mediated diseases continue to require therapies capable of delivering deeper and more durable disease control. He noted that Sail’s in vivo CAR-T platform offers a simplified and scalable approach to CAR-T therapy that could accelerate development of treatments capable of fundamentally changing how these diseases are managed.
The company also disclosed that, assuming the acquisition option is exercised, the transaction is expected to reduce adjusted operational earnings per share and adjusted earnings per share by approximately $0.18 in 2026 and approximately $1.28 in 2027.
Future Development
The collaboration remains subject to applicable regulatory approvals and other customary closing conditions. Johnson & Johnson will initially focus on advancing Sail’s lead immune-mediated disease program while evaluating broader applications of the in vivo CAR-T platform across additional therapeutic targets.
If successful, the partnership could accelerate the clinical development of scalable in vivo CAR-T therapies that eliminate many of the logistical challenges associated with conventional autologous CAR-T treatment while expanding the use of cell therapy beyond oncology into chronic immune-mediated diseases.
Reference
About the Writer
Umesh Hanumante (M.Pharm) (LinkedIn) is a pharmacy professional and healthcare writer with a background in Regulatory Affairs, pharmaceutical innovation, and clinical research. He has around two years of industry experience as an Executive PMT at Troikaa Pharmaceuticals Ltd and qualified GPAT 2024. His areas of interest include regulatory compliance, dossier preparation, clinical trials, emerging therapies, and advancements in the global pharmaceutical and healthcare sector.
